Rakovina Therapeutics, Inc. announced that the company has been selected to join a three year US $975,000 research program funded by the St. Baldrick’s Foundation Martha’s BEST Grant for All, which is aimed at developing new treatments for Ewing sarcoma, an aggressive bone and soft tissue cancer in children and young adults.
[Rakovina Therapeutics, Inc.]